Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexist

This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting SARDs when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites (www.rheum.ca, www.canrio.ca). (PROSPERO registration: CRD42023461024).

Authors

Institutions

Publication Details

Journal
The Journal of Rheumatology
Published
2025-09-15
DOI
https://doi.org/10.3899/jrheum.2025-0482
Citations
3
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
4.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexist

Jeffrey Graham, Alexandra Ladouceur, Jordi Pardo Pardo, Nancy Maltez et al.
3 citations
The Journal of Rheumatology
Chronic Lymphocytic Leukemia Research
4.88
article

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexist

Jeffrey Graham, Alexandra Ladouceur, Jordi Pardo Pardo, Nancy Maltez, Janet Roberts, Keith C.K. Lau, Janet Pope, Sabrina Hoa, Glen Hazlewood, Alexandra Kobza, May Y. Choi, Alexandra Saltman, Shahin Jamal, Megan E. Himmel, Carrie Ye, Lourdes Gonzalez Arreola, Faiza Khokhar, Liam J. O’Neil, Inés Colmegna, Roko P.A. Nikolic, Aurore Fifi‐Mah, Marie Hudson, Dirk Velthuizen
article en
3 citations

Abstract

This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting SARDs when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites (www.rheum.ca, www.canrio.ca). (PROSPERO registration: CRD42023461024).

The Journal of RheumatologyVol. 52(12)
Western University (CA), Dalhousie University (CA), University of British Columbia (CA), University of Ottawa (CA), University of Alberta (CA), University of Calgary (CA), University of Toronto (CA), Alberta Hospital Edmonton (CA), Research Canada (CA), Alberta Bone and Joint Health Institute (CA), Arthritis Research Centre of Canada (CA), University of Manitoba (CA), McGill University (CA), Université de Montréal (CA), McMaster University (CA)
Canadian Rheumatology Association
Openalex Percentile: Top 5%
Chronic Lymphocytic Leukemia Research
4.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.